Mahmoud I. Khalil

Mahmoud I. Khalil

Auto-generated profile, based on publicly available information

Mahmoud I. Khalil

Department of Urology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MKMahmoud I. Khalil
Mahmoud I. Khalil
MKMohamed H. Kamel
Mohamed H. Kamel
JDJasreman Dhillon
Jasreman Dhillon
VMViraj Master
Viraj Master
RDRodney Davis
Rodney Davis
Philippe SpiessPhilippe Spiess
Philippe Spiess

1 September 2019 in Urology
Verified
Journal Article
Closed access
MKMohamed H. Kamel
Mohamed H. Kamel
MKMahmoud I. Khalil
Mahmoud I. Khalil
RDRodney Davis
Rodney Davis
Philippe SpiessPhilippe Spiess
Philippe Spiess

1 January 2021 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
MKMahmoud I. Khalil
Mahmoud I. Khalil
ABAustin K. Bramwell
Austin K. Bramwell
NBNaleen Raj Bhandari
Naleen Raj Bhandari
NPNalin Payakachat
Nalin Payakachat
Bruno MachadoBruno Machado
Bruno Machado
OROmer A. Raheem
Omer A. Raheem
Khalil MI, et al. World J Mens Health. 2021 Jan;39(1):75-82. https://doi.org/10.5534/wjmh.190172

27 July 2019 in International Urology and Nephrology
Verified
Journal Article
Closed access
MKMahmoud I. Khalil
Mahmoud I. Khalil
JAJeffrey T. Alliston
Jeffrey T. Alliston
JBJonathan J. Bauer-Erickson
Jonathan J. Bauer-Erickson
RDRodney Davis
Rodney Davis
NBNabil K. Bissada
Nabil K. Bissada
MKMohamed H. Kamel
Mohamed H. Kamel

3 March 2024 in BJUI Compass
Verified
Journal Article
Open access
MKMahmoud Khalil
Mahmoud Khalil
AFAndrew Fishman
Andrew Fishman
AKAnna Komorowski
Anna Komorowski
IFIsrael Franco
Israel Franco
MGMichael Grasso
Michael Grasso
Objective: The aim was to evaluate the role of immune check point inhibitors (ICIs) in patients with high‐grade upper tract urothelial carcinoma (UTUC) who are managed endoscopically when nephroureterectomy (NU) is not feasible, such as in patients who are either not candidates for NU or decline extirpative surgery.Methods: All patients diagnosed with high‐grade UTUC and managed endoscopically between January 1996 and August 2022 were included in the study. Subsequently, patients were categorised based on their use of ICIs into group 1 (patients who did not receive ICIs) and group 2 (patients who received ICIs). Survival outcomes were assessed using Kaplan–Meier analysis, while a multivariable regression model was employed to analyse the impact of clinical characteristics on survival.Results: A total of 29 patients were enrolled, with 14 in group 1 and 15 in group 2. Both groups exhibited similar demographic and disease characteristics, including multifocality, laterality and initial tumour size. The median follow‐up period was 29.2 months. Notably, group 2 demonstrated significantly enhanced overall and metastasis‐free survival rates compared to group 1. At 47.8 months, the overall survival rate was 0% (all patients died) in group 1, whereas it was 85.7% in group 2. Similarly, the metastasis‐free survival rate was 0% (all patients had metastatic disease) in group 1 at 40.6 months, whereas it reached 78.0% in group 2. The multivariable analysis indicated a correlation between ICI usage and improved survival outcomes, with a hazard ratio of 0.002.Conclusion: Utilisation of adjuvant ICIs in the setting of endoscopically treated patients with high‐grade UTUC is associated with significantly improved survival rates. ICIs should be considered in this patient population, however, more studies with larger sample size are warranted.

24 November 2022 in Current Bladder Dysfunction Reports
Verified
Journal Article
Closed access
PDF file
MKMahmoud I. Khalil
Mahmoud I. Khalil
MAMohamed N. Alnoomani
Mohamed N. Alnoomani
MGMichael Grasso
Michael Grasso